Anacor Pharmaceuticals developed and commercialized novel therapeutics with its boron chemistry platform. The foundation partnered with the team to support development of preclinical drug candidates for filarial diseases, tuberculosis, and cryptosporidiosis as well as expand the company’s boron chemistry compound library for evaluation against priority disease assays.
Investment Exit Year: 2016